Compugen Stock Price, News & Analysis

Compugen Ltd. (NASDAQ: CGEN) announced the advancement of a bispecific antibody derived from COM902 into clinical development by AstraZeneca, which will evaluate AZD2936 in patients with advanced non-small cell lung cancer. AstraZeneca holds exclusive rights for the development of products based on COM902, while Compugen retains rights for monotherapies and combination treatments. Compugen has received a $10 million upfront payment and $2 million in milestone payments, with a potential of up to $200 million in future milestones.

Compugen Ltd. (NASDAQ: CGEN) released its financial results for Q2 2021, reporting a net loss of $9.5 million, up from $6.2 million in Q2 2020. R&D expenses rose to $6.8 million from $4.4 million year-over-year. Compugen initiated three clinical studies for its anti-PVRIG, anti-TIGIT, and anti-PD-1 combination therapies, highlighting its leadership in the DNAM axis space. Cash and equivalents totaled approximately $111 million as of June 30, 2021. Upcoming data readouts are expected to enhance the company's clinical data foundation.

Compugen Ltd. (CGEN) has announced the dosing of the first patient in its Phase 1/2 study, which evaluates the triple combination of COM701, Opdivo®, and BMS-986207. This study aims to assess the safety, tolerability, and preliminary antitumor activity of this novel therapy targeting PVRIG, TIGIT, and PD-1 pathways, believed to enhance anti-tumor immune responses. The cohort expansion phase focuses on specific patient populations, with preliminary data expected by Q4 2021. Compugen partners with Bristol Myers Squibb for this innovative immunotherapy approach.

Compugen Ltd. (CGEN) has announced the dosing of the first patient in a Phase 1 clinical study assessing the combination of its anti-TIGIT antibody, COM902, and anti-PVRIG antibody, COM701, in patients with advanced malignancies. The study aims to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients who have exhausted standard therapies. Initial results from the COM902 monotherapy study are expected in Q4 2021. Compugen's strategy focuses on expanding immunotherapy effectiveness through dual blockade of PVRIG and TIGIT pathways.

Compugen Ltd. (Nasdaq: CGEN) announces it will release its second quarter 2021 financial results on July 28, 2021, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. The call can be accessed via telephone or through a live webcast on the company's website. Compugen is focused on cancer immunotherapy with key products like COM701 and COM902 undergoing clinical studies.

Compugen Ltd. (NASDAQ: CGEN) has announced the dosing of the first patient in a combination expansion cohort of its Phase 1 clinical trial for COM701, an anti-PVRIG antibody, in conjunction with Opdivo® (nivolumab). This cohort targets ovarian, breast, endometrial, and colorectal cancers, following encouraging initial results showing complete responses and durable anti-tumor activity. The trial aims to evaluate the safety and efficacy of the therapy in advanced solid tumors, reinforcing Compugen's position in cancer immunotherapy.

Compugen Ltd. (CGEN) presented new research on PVRIG, emphasizing its role as a distinct immune checkpoint that may enhance T-cell expansion. Findings suggest that PVRIG clusters with early memory T cell markers, indicating its potential when used with TIGIT and PD-1 inhibitors for tumors unresponsive to current therapies. The study highlights PVRIG's expression in T cells and its potential to trigger immune responses. The presentation was made at the SITC 2021 seminar.

Compugen Ltd. (Nasdaq: CGEN) presented updated data from its Phase 1 study of COM701, a first-in-class anti-PVRIG antibody, at ASCO 2021. The combination of COM701 with Opdivo® demonstrated a 66.7% disease control rate in 15 evaluable patients, with a notable complete response in a patient with anal squamous cell carcinoma lasting 22 months. The monotherapy showed a 47.2% disease control rate across 36 patients, with preliminary biomarker data indicating enhanced immune response. These findings highlight the potential for COM701 in difficult-to-treat cancers, including ongoing evaluation in immunotherapy-resistant populations.

Compugen Ltd. (Nasdaq: CGEN) announced participation in a virtual event to discuss data from its Phase 1 clinical trial of COM701, an innovative antibody targeting PVRIG. The findings will be presented on June 7, 2021, at the ASCO 2021 Annual Meeting. A fireside chat hosted by Truist Securities analyst Asthika Goonewardene is scheduled for June 8, 2021, featuring key executives from Compugen. The company is focused on developing cancer immunotherapy treatments, including the ongoing studies of COM701 and COM902.